PARSIPPANY, NJ--(Marketwire - May 14, 2008) - Daiichi Sankyo, Inc. announced today that data presented at the American Society of Hypertension’s Twenty-Third Annual Scientific Meeting (ASH 2008) in New Orleans demonstrates that a cumulative 45 percent of patients with stage 1 hypertension treated with a regimen of BENICAR® (olmesartan medoxomil) and BENICAR HCT® (olmesartan medoxomil/hydrochlorothiazide) were able to safely and effectively achieve a normotensive blood pressure, < 120/80 mm Hg (placebo: 1.4%). The Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC 7) defines this level as normotension.
